| Execution period | FY 2026-27 |
|---|
BSE filing, NSE: ANUHPHR. Summary written from the filing by ALFA Finder's alert engine.
Anuh Pharma Ltd: key numbers
- Share price
- ₹79.61
- Market cap
- ₹797.9 Cr
- Revenue (annual)
- ₹771.7 Cr
- Net profit (annual)
- ₹41.05 Cr
- P/E (TTM)
- 18.1×Sector 46.1×
- Promoter holding
- 71.80%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anuh Pharma Ltd
All →Anuh Pharma Board Meeting Date
Anuh Pharma's board meets on 30 October 2026 to approve Q1/H1 FY27 results. Trading window closed for insiders until 1 November 2026.
Anuh Pharma Acquisition Worth ₹72.9 Cr
Anuh Pharma signed an Asset Transfer Agreement to acquire a manufacturing facility from Vanquest Pharma for ₹72.90 Crore, increasing its production capacity by 525 MTPA.
- Value
- ₹72.90 Cr
- manufacturing capacity
- 525.0 MTPA
Anuh Pharma Debt & Borrowing: ₹75 Cr
Anuh Pharma Ltd board approved a loan of ₹75 Crore to finance manufacturing asset investments for expanding production capacity.
- Value
- ₹75.00 Cr
Anuh Pharma Other Announcement
Anuh Pharma Ltd filed the quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as issued by its RTA.
Anuh Pharma Legal & Regulatory
Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.
- Value
- ₹0.10 Cr
Anuh Pharma Investor Presentation: Key Takeaways
Anuh Pharma reported strong Q1 FY27 results with 4% YoY revenue growth and 38% PAT growth, driven by a shift to high-value regulated markets.
- Call
- Guides 18% growth
Other debt & borrowing announcements
All →Fusion CX Debt & Borrowing: ₹21.85 Cr
Fusion CX lent up to Rs.21.85 Crore (USD 2.3 million) to wholly owned subsidiary Fusion BPO Services. Terms: 8.5% interest, three-year tenure, unsecured.
- Value
- ₹21.85 Cr
- Execution
- 3 years from the date of disbursal
Fusion CX Debt & Borrowing
Fusion CX Limited executed an unsecured inter-corporate term loan at 8.5% p.a. for three years with its wholly owned subsidiary Fusion BPO Services Ltd, a related party. Amount is not stated in the filing.
- Execution
- 3 years from the date of disbursal
Spandana Sphoorty Financial Debt & Borrowing: ₹0.49 Cr
Spandana paid ₹0.49 Crore of quarterly interest on its secured NCDs on 27 October 2026. The coupon rate is 10.75% on a ₹50 Crore issue.
- Value
- ₹0.49 Cr
Mangalam Worldwide Debt & Borrowing: ₹1.14 Cr
Mangalam Worldwide paid Rs. 1.14 Crore interest on its NCDs (ISIN INE0JYY07026) on 28 October 2026, net of TDS. The company confirmed timely payment under Regulation 57.
- Value
- ₹1.14 Cr
Lloyds Metals & Energy Debt & Borrowing: ₹12,370 Cr
Lloyds Metals allotted 1,300 debt securities worth about ₹12,370 Crore on 29 October 2026. Three-year coupon is SOFR plus 450 bps, secured by Virtus Lloyds share pledges.
- Value
- ₹12,370 Cr
- Execution
- 3 years
Lloyds Metals & Energy Debt & Borrowing: ₹1,235 Cr
Lloyds Metals' committee approved terms for USD 130 million senior secured notes, about Rs.1,235 Crore. The notes mature in October 2029 at SOFR plus 450 bps.
- Value
- ₹1,235 Cr